China's traditional Chinese medicine industry as a whole is facing internal and external problems

[market analysis of China Pharmaceutical network] in recent years, the scale of traditional Chinese medicine industry continues to rise It is estimated that by 2020, the overall scale will exceed 3 trillion yuan, and the annual compound growth rate will remain at about 20% And after the introduction of the new "Chinese medicine law", the development of the great health industry of traditional Chinese medicine has entered a golden period In 2017, the market size has reached 1750 billion yuan, an increase of 21.1% year on year However, there are still many challenges in the development of traditional Chinese medicine Although the scale of traditional Chinese medicine industry continues to expand, the problems of chaos in traditional Chinese medicine industry need to be solved For example, as one of the sub industries of traditional Chinese medicine industry, the profit level of Chinese herbal pieces is growing rapidly Data shows that in 2018, the market scale of Chinese herbal pieces will reach 273.4 billion yuan, up 17% year on year In addition, Chinese herbal pieces have a certain substitution effect on Chinese patent medicines, and will continue to maintain rapid growth in the short term However, due to the lack of a unified division standard, Chinese herbal pieces have become a major disaster area Relevant people said that the low concentration of the industry is a major feature of the Chinese herbal medicine industry, with 70% of the enterprises with sales less than 100 million yuan In the market, many small-scale enterprises of Chinese herbal pieces have been transformed from traditional manual workshops, which follow the backward production and management methods There are various problems in the quality of raw materials, processing technology, packaging, storage and transportation of drugs, which directly affect the clinical efficacy and safety of Chinese herbal pieces It is reported that in the market of Chinese herbal pieces, the phenomenon of counterfeiting, dyeing and adulteration, weight gain, and beyond the scope of business occurs from time to time, which disturbs the order of fair competition in the market For enterprises, it is even more "throwing stones at their own feet" In order to improve the quality of Chinese herbal pieces and strengthen market supervision, Henan, Gansu, Guangxi, Jiangxi, Heilongjiang, Anhui, Sichuan, Hainan, Jiangsu and other provinces and regions have issued a centralized treatment plan for Chinese herbal pieces Under strict inspection and supervision actions, the industry has been treated to a certain extent Data shows that China has more than 70 listed companies of traditional Chinese medicine, with a total market value of nearly 740 billion yuan In addition to the problem of Chinese herbal pieces, the Chinese herbal medicine industry as a whole is facing the situation of internal and external troubles Among them, the internal problem is that the quality of traditional Chinese medicine needs to be improved Since 2018, there have been many negative events in traditional Chinese medicine industry, which urge the quality and supervision of traditional Chinese medicine in China to be improved, and the construction and improvement of industry standardization is even more urgent In order to improve the quality of traditional Chinese medicine and standardize the production and processing standards Some pharmaceutical enterprises start from Chinese herbal pieces, work together with the relevant departments of the state to formulate the quality standards and production and processing standards of Chinese herbal medicine industry, the modernized production base of Chinese herbal pieces that have passed the national GMP certification, and the total number of drugs, medical devices and Chinese herbal pieces that have passed the national GMP certification is more than 7000, so as to gradually realize the standardization of Chinese herbal medicine industry But the outside is facing the public opinion of Japanese, Korean and Chinese medicine and the siege of standardization power In fact, most of the herbal medicines in the products of Japanese and Chinese enterprises are imported from China In order to facilitate production and ensure product quality, these enterprises have established many gap planting bases in China
Compared with Chinese medicine in Japan, Chinese medicine enterprises in Japan will invest a lot of manpower and material resources in the research of pharmacology, toxicology, standardization and standardization of dosage form composition analysis However, there are still some deficiencies in these aspects in China Therefore, in terms of standard formulation, innovation, and quality control, Chinese medicine industry needs to make more efforts to occupy a larger share Market.